Jefferies downgraded Biogen (BIIB) to Hold from Buy with a price target of $180, down from $250. The firm sees a “tough setup” into 2025 for Biogen with modest Leqembi and Skyclarys US. It see a “real need” for more pipeline and “serious” business development to get investors re-engaged in the shares. Investors haven’t bought into Leqembi and Jefferies doubt 2025 convinces the Street, the analyst tells investors in a research note.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BIIB:
- SPY ETF Update, 12/6/2024
- GeneDx expands access to exome testing for pediatric epilepsy patients
- VOO ETF Update, 12/5/2024
- Eisai, Biogen say LEQEMBI approved for treatment of early AD in Mexico
- QQQ ETF Update, 12/4/2024
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
